<SUBMISSION>
<ACCESSION-NUMBER>0001193125-08-022823
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>3
<PERIOD>20080206
<ITEMS>5.02
<ITEMS>9.01
<FILING-DATE>20080207
<DATE-OF-FILING-DATE-CHANGE>20080207
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>AtriCure, Inc.
<CIK>0001323885
<ASSIGNED-SIC>3841
<IRS-NUMBER>341940305
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>000-51470
<FILM-NUMBER>08584433
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>6033 SCHUMACHER PARK DRIVE
<CITY>WEST CHESTER
<STATE>OH
<ZIP>45069
<PHONE>513-755-4107
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>6033 SCHUMACHER PARK DRIVE
<CITY>WEST CHESTER
<STATE>OH
<ZIP>45069
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d8k.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML><HEAD>
<TITLE>Current Report</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P
STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:3px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P
STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>FORM 8-K </B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>PURSUANT TO SECTION 13 OR 15(d) of the </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>SECURITIES EXCHANGE ACT OF 1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="2"><B>Date of Report (Date of earliest event reported): February&nbsp;6, 2008 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P
STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="6"><B>AtriCure, Inc.
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Exact name of registrant as specified in charter) </B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>000-51470</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>34-1940305</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(State or other jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="1"><B>of incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Commission File Number)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>6033 Schumacher Park Drive<BR>West Chester, OH</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>45069</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Address of principal executive offices)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Zip Code)</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Registrant&#146;s telephone number, including area code: (513)&nbsp;755-4100 </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Not Applicable </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Former name or
former address, if changed since last report) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P
STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:3px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P
STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>Item&nbsp;5.02.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. </B></FONT></TD></TR></TABLE> <P
STYLE="margin-top:6px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">On February&nbsp;6, 2008, the Board of Directors of AtriCure, Inc. (&#147;the Company&#148;) appointed Mark A. Collar as a director of the Company, effective
February&nbsp;6, 2008, to serve until the 2008 annual meeting of stockholders of the Company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">In connection with his appointment, Mr.&nbsp;Collar has been
granted the same compensation as other non-employee directors, including an option to purchase 50,000 shares of the Company&#146;s common stock and an option to purchase 10,000 shares of the Company&#146;s common at each annual meeting of
stockholders, provided he has been a director for at least six months. These options have been and will be granted at an exercise price equal to the fair market value on the date of grant. The initial option grant has a term of ten years and vests
one-fourth on each anniversary of the date of grant. Subsequent option grants generally have a three-year vesting schedule. Mr.&nbsp;Collar will receive an annual retainer of $20,000 plus $1,500 for each in-person meeting attended and $500 for
participation in a meeting via telephone. If Mr.&nbsp;Collar serves on a Committee, as a non-chairperson member, he will also receive $750 for each in-person meeting attended and $350 for participation in a Committee meeting via telephone.
Additionally, he will be entitled to reimbursement for all out-of-pocket expenses related to his services as a director. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The Company issued a press
release on February&nbsp;7, 2008 announcing Mr.&nbsp;Collar&#146;s appointment, a copy of which is furnished as Exhibit 99.1. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>Item&nbsp;9.01.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Financial Statements and Exhibits. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">(d) Exhibits. </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="95%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:11pt"><FONT FACE="Times New Roman" SIZE="1"><B>No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">99.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Press Release of AtriCure, Inc. dated as of February 7, 2008.</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">ATRICURE, INC.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-bottom:1px;border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="2">/s/ Julie A. Piton</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Julie A. Piton</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Vice President and Chief Financial Officer</FONT></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Dated: February&nbsp;7, 2008 </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>EXHIBIT LIST </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:11pt"><FONT FACE="Times New Roman" SIZE="1"><B>No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Press Release of AtriCure, Inc. dated as of February 7, 2008.</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px">

<IMG SRC="g11615img001.jpg" ALT="LOGO"> </P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Contact: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><I>AtriCure, Inc.
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Julie A. Piton </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Vice President and Chief Financial
Officer </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">(513) 755-4561 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><U>jpiton@atricure.com</U> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Press Release </B></FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>AtriCure Appoints Mark A. Collar
to its Board of Directors </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">WEST CHESTER, Ohio &#150; February&nbsp;7, 2008 &#150; AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader
in cardiac surgical ablation products, announced today the appointment of Mark A. Collar to the Company&#146;s Board of Directors. Mr.&nbsp;Collar recently retired from a distinguished career with The Procter&nbsp;&amp; Gamble Company, including
recently serving as President of the Global Pharmaceuticals and Personal Health business. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">&#147;We are pleased to add Mark to the Board of Directors of
AtriCure,&#148; said Richard Johnston, Chairman of the Board of AtriCure, Inc. &#147;We welcome Mark and his extensive, broad-based business experience to our board, specifically, his experience in the life sciences sector. We believe Mark will
immediately contribute and bring value to AtriCure.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Mr.&nbsp;Collar, 54, joined Procter&nbsp;&amp; Gamble in 1975 as a sales representative and
assumed roles of progressive responsibility within their Health&nbsp;&amp; Personal Care, Beauty Care, New Business Development, and Personal Health Care Products divisions. Mr.&nbsp;Collar moved to the Pharmaceuticals division in 1994 and was named
President of Global Pharmaceuticals in 2002. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Mr.&nbsp;Collar is currently the Chairman of the Third Frontier Advisory Board, which provides direction for
the state&#146;s 10 year $1.6 billion investment in high tech research, innovation, and company formation. He is also Vice Chairman and a Member of the Executive Committee for BioOhio, Inc., a non-profit organization which promotes the acceleration
and growth of life science companies in Ohio. Further, Mr.&nbsp;Collar is a Trustee and Member of the Executive Committee for the Health Alliance, a leading hospital group serving the greater Cincinnati area. </FONT></P> <P
STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><U>About AtriCure, Inc. </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:3px;line-Height:95%; vertical-align:top"><FONT
FACE="Times New Roman" SIZE="2">AtriCure, Inc. is a medical device company and a leader in developing, manufacturing and selling innovative cardiac surgical ablation systems designed to create precise lesions, or scars, in cardiac, or heart, tissue.
Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure Isolator<FONT FACE="Times New Roman" SIZE="1"><SUP>&reg;</SUP></FONT> bipolar ablation system as a treatment alternative during open-heart surgical
procedures to create lesions in cardiac tissue to block the abnormal electrical impulses that cause atrial fibrillation, or AF, a rapid, irregular quivering of the upper chambers of the heart. Additionally, medical journals and leading
cardiothoracic surgeons have described the AtriCure Isolator<SUP>&reg; </SUP>system as a promising treatment alternative for patients who may be candidates for sole-therapy minimally invasive procedures. AF affects more than 2.5&nbsp;million
Americans and predisposes them to a five-fold increased risk of stroke. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0px;margin-bottom:0px;padding-bottom:3px;line-Height:95%; vertical-align:top"><FONT FACE="Times New Roman" SIZE="2">The FDA has cleared the AtriCure Isolator<FONT
FACE="Times New Roman" SIZE="1"><SUP>&reg;</SUP></FONT> bipolar ablation system, including the new Isolator Synergy<SUP>TM</SUP> ablation clamps and the AtriCure multifunctional bipolar Pen, for the ablation, or destruction, of cardiac tissues
during surgical procedures. Additionally, the FDA has cleared the AtriCure Pen for temporary pacing, sensing, stimulating and recording during the evaluation of cardiac arrhythmias. To date, the FDA has not cleared or approved AtriCure&#146;s
products for the treatment of AF. AtriCure&#146;s left atrial appendage clip system has not been approved for commercial use. It is currently being used in clinical evaluations in Europe. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B># # # </B></FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g11615img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g11615img001.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`,@#R`P$1``(1`0,1`?_$`.,```$#!`,!````````
M``````D'"`H`!08+`0,$`@$``00#`0$`````````````"``&!PD#!`4"`1``
M``4"!`(#"@<)"0P+`````0(#!`4&!P`1$@@A,5$3"4%AD2(R,Q0U-C=Q8F,T
M%3@*@:&QP=%2(U,6X4*R5&1E)T<Y<D.C1'2T)46UMAAX)D969G:&%W>G*&@1
M``$"!`0"!@4(!@8(!@,```$"`P`1!`4A,1(&00=188$R$PAQ(D(S-)&AL5)B
M%!4UP=%R@B,V\/%#@T06LG.3LR1T)47ADL)D91<F1C?_V@`,`P$``A$#$0`_
M`)^0B.8\1YCW<*%'&8](^$<*%`?NV1WWUQLFL111[/3$9$7HNA6R<52[R4BV
M$\VBZ8IUN64K"74AY$JK5UJ(NU9)B<A@(H\U<R8DWE;LVEWA>W&[BE9MS#<U
M:9B95W<?E^:(BYP[ZK-E6)IRV*0FXON>KJX`9X=?Z##`NR'[6?<%N3W+2EBM
MS]9T]/DK2BI!_:]Y%TK`4FHVJZF%`E)*(5&'1:E??3-.>D*I@H!A*=ED7RA`
M7MS5Y86K;-F9O&WVWDM-KTNA9*B9Y*ZDX@>F&%RBYMW7=&XG+)N-UM3CK(4T
M4`)2#.6G`=[`_*(D^@)LQS$>YD.8Y#\&![U341+`2^>"<4!(2SCG,>D?"./L
M>8^3*`0,S&$`SRSSR\(YAPQY5XF'AB:IQ]PD22`D"9)BWQ4Q%SC!I+PLDTEH
MJ12!PPDHYVF]8O6XB8"KM72!U$%T3"4<CD,)1RX#CVMIUAPH>!#O$'AV1C;<
M+R/$1I+/`CC%RS'I'PCCY'N*S'I'PCA0HK,>D?".%"C`KI58^H2VMPJWCHQQ
M./Z,H>K*K8PC83"XFGE.P$A+MHI$"9J"H_69E2`"@)LS\..,EO;%76TS#ITH
M>?2E1^J"0"?TQS+E5O45OJ:AE)6XS3J4D?64`2/GB`TGVQ?:&FN*C=C_`(A*
ME.!9=.H36Y*QAQMFLQUBX/2Q*7)'')]#':@"(*"J+L0,)P6ZP,\&NOE1LA=D
M-$FF`6A"E!\2U*D)@ZL_G@$$\X=ZM;F%6JM?*%.)2:<J44)).(T98991/XH2
MH7%6411M5.6:L8YJ:E:>J%Q&JF4%6.7FHEI)*L%!4`J@G9J.13'4`&S+QXX"
MNI812U+E,V24-N*2"<20"1C!\4+ZJJB9J5RUN-)49934D&++<^Z5$V?I"3KB
MOYU*"@(TI2F54UK.GSM0!]&C8IDF(N)"2>'#2FBF`F'B(Y%`3`U=T[LL>S+0
M[?=P/H8H&DSFJ4UGH2,R>$=ZS62Z;AN#=JM3*WZMQ7JA,\.M1Z("?>+M1[J5
M3(+Q-E85I0L&HJ=FRDY*/3J6L9%0P&*B9-H;K8J-46T^(F5-R<!X:A-R"'=_
MFIW1>*G[EL2G2TRL30LHUK4-1$P)83]$%[M7RY6"VTB;CO5]3SHQ6VE6A",.
MZ3G,<<9=4)<SJ3M)ZP:#-L7FX9VP,/I(KM6JT(F`'*!R>C,DVL:<R)BCF4H)
M"40PRW[OYFKXW^)4RKR&E"<TE3:/W4`B8[(<"F/+U:7_`+DM%K)&$B0XH$9Z
MU&>/;&,,MY>]"TL]Z%4M<58#U`X@I3]S:;1<%5`A@!1,49./82`IY\.L27`.
MX!@QS6^=7.[8KJ'K_5/N(0L`MU""=72`2,XW3RIY2[R96;*RVEQ:1H53K`TF
M>:D@RET89P=C:=>V:W`V8@KDU!$,8.8>R$U$OF48X<+,#JPSX6@/&X.?TR(.
MB@!A3,)M`\`$>>#]Y4[VJN8&S:7<E>VEBL=+@*$Y$`C'L@--_P"U6MG;KJK&
MRXIUMDB1/6.C*?9#E,QZ1\(XDJ&9%9CTCX1PH45F/2/A'"A168](^$<*%%9C
MTCX1PH45F/2/A'"A168](^$<*%%9CTCX1PH45F/2/A'"A168](^$<*%%9CTC
MX1PH4=^%"CH'F/PC^'"A1UGSTCEGGEGXO$PY!GD'?''V:4D:LB90LBF>4_FE
M$&WM3KBU=OT[32.L';`WTTUHJH(3;O;Q(%#JQIJD._,M7U1KG;ZB)LDI]59-
MRX*`@5I&@(B.G+!B<LZ>BV5L)5[N*0A3R5/N3G,H!DE/_E`.$H!OFO75',+F
M(FPVDE:67`PA(Q"3[2A^]/.<H%51%75YMBO_`$S63)!:+N%82ZC=XX8G`R*B
M$[0M0&:SL4J4^A46L@1BNU4*8"B=)8<PXXD2Y,4>[-N.4YD\S6T\D$DF1(U`
MX'@"!V1%-I=N.S=X)K@5-F@J9*2``2`9$93Q()[8V5EK+B4_=RV]"W1I-T1[
M3%PJ3@:P@G!#E.`Q]01K>211.)1$I5VP+]6H7F4Y!`>(8`.XT+MLK7;>^"'F
M5J01UI,I]N8BRNU5]/=;8Q=*8@MU#:5X=8R[,O3&>&,!0X_C[GP9XT3]8F2!
MG&ZHG)/?.41K>VK[4]6U\94&T#;O4B?_`*D3<<NRO+7D*[*96WM/R*)R'HB&
M=('U)5I-LU!]-5*)31C,V0?IE`%,@.4'+7\8JD;@W`@)MR3-I"I^N1B%\,!+
M#I./1`W<Z>;;5EI%[>V^HKN*I!U:2/4!P*?U_)!<.SXJ2FFFQG:2V<5#!-UT
M=OUKDU45I>/2634"E8[4FJDHX*<ARCP$!`!`>88B;>M&^K=->Y3(6$A\@229
M2!RREE$N[(N-&=I6_P"\/MAXL`F:Q.9GB9F?'C#UFSYF\1(Y9O6[UL<3`1PT
M72<MU!*;28H+("HF8Q3<!`!S##7<3)6I:BW+,0\Z=0<;)04N`Y*!&/5AA&$5
M?=NV-`35+TW6U?TC2U15Q-,:<HRGYN>CV,[5,Y)*@@RC(*'57"1DG+A4=(`D
MF8`YB(!C<I;;<*IMVIIVG7*5D36H).E(Z5*E(?+&M5W.VTCS5)4/-MU;QDE)
M4-1/4.,>.Z-[+061A25#>"YU#6RAE3'(A(5M4L53J#M1/BHFR"2<H*/3D`>(
M)%.(!W,9:&VW"XGPZ%AQ]X9A"5*^@&,-PO%JM*0Y<ZAMAKI6H`F/FV%X[17S
MIM:J+1W)HFZ-+@N=@YE:,J",J..0="B!SL'YHY=<&S@R)M0HK`4XD'/+(<8:
M^W5]H=*+BTXP\HA20L%)[,`8]VVY6R[LA5N>;?:2-*B@@CM@<=P^SE[*VS->
M#N1N?;NV=N%&DX2HTR5?6\A`VT&H"NR.DW[.A)";0IUTZ4?:5",TFYT#*Y`"
M`@.D7Q1;]W_<;?\`A5/45"Z1#>F2$@D)E]8)F!+B<>N<1U7\O>6MMNGXQ<6*
M=JN<=U#4H@*459Z2K$SQPPZH+`9TU;,#/U7"2+%!J9VJY.8I$$&B:0K'6,<0
M(4J"2)1-GD``4.YB-'G?NB7:JK44TZ`I9GP`Q()^6)5;`?2EJE2-:M*4A.6,
MI2B+_N\W'36Y"ZS]U'NGBE!T^Z6A;>PB*B@D70(L+8\V9F0-*DM42Q->HP"=
M-`R:1>&K.K/G1S(N7,O="[?2ZW;*V[X3+?LA0P*@!F2<<9Q8=RLV%0\O]LM7
M*M*/Q=ULN.JXA)Q"9G(`882Z>,&)V6;-J9LM2,-6M:0<;,7@G&B3]Z^?MTW(
M4:T=$*LA`P952J)-739,2BZ<%*"BB^90$"%`!,CD?R6M6S+%37:Y--/WUY(<
M4M:9J0%`20`?5`$IX#,P*W-7FC=-VWJHHK<\XSMU"]"6TJ(2X4DS<)[QU3E(
MDB0$$$`H`.KN]/'[_'C@CI@D2!``D.`^3+YHA<(0F8`&.9S)[<X2*]-E*!OI
M1DA1M=0K9^BZ;KDC)@$B?3%.R)DS`UEHA\(=>V<M%A`V0#H.`:3`)1$,,_>F
MR;%OBRO6>\4S+NM"M"E)Q0N1DH$2((].,.?:^[KQLVY(NUI><;4A:=24GU5I
MU":5#$$=<IB$<V8T!*V6LP\M]5KEND^I.XE=1IGZYBLFDDS4EP<1LHWZX2$*
ME(LE4U2ES\43"7CEAH\G-O.;*V8-O7!83]VJ'`%$RP)PQ/`QW.9=]I]U;M7?
MZ=)2FJ90J0QDK2-4P.(.<.J-4,"'*<A^_G)L@$`[@^>Y8DO\8LP25&L8*00#
M)Q!(),I2'7A#$3352@=#3BG.`TD3_H(NFLHEU`/BZ=0&`P"7+IU!F''&\I1T
M_P`-22`)S.1^3A&!"5J&OVIRT]?1%N7F8ELH*+F5CFRY0#4@N^:HK%#(!S,F
MJJ0Y?%'/B`<,:E17TE*L,UE0PTZ<0"H`GL)XQ];8JGDEUI"E)!D0`3+ME'H;
M2#![K]#?-'G5B'6>B.47/5Y@(AUG4'.),](Y9Y9Y8S-UE.^)TZT.`_5(,ODC
MTMIQ@I#B5@JRU"7ZH[C+)D(<YS@0I"B910Y@*5,I<Q$QA-I`I0`.(CP#&=;J
M6&_&JBA#0]K5ZORF,3"T.'U"I:OJR];Y!&+TY75'5>ZFF=+53"5$YIEVBPJ!
M*&D6TC]$OG*(N$&CY1H99)%R=`!/HU:@+SRQS:"]6FYJ6S;ZENH4A1U*;(4$
MR]E1!(!&73Z(WZZW7*W>']\86R'4ZDAP%*B#E('YNGT1A<KN`LA"5$2E)>[=
MOHZHC+^C!#N:IB"/"N-0$]'53!R((N-8Z=!A`V?<QQWM^;.I;F+2]<:;[\I4
MM&L32KZO1CUQTZ?:>YWZ156+?5_=93"_#5BGIRE*%?34*H0#E-J*;B4P"&1B
MCQ`P"&8"`AR'NX=R2E6*2DB4\#A(XB&XE:7)I]9"@2#/.8P.$816-SK=6\13
M7KJN:5I%-4,T?V@G(Z,47#CQ;MW2Z;AP`9<R%,&&]>-T[>LGJ72NI*9R4Y.+
M`,NF4Y_-'4M]HNUU<E;J6H?0,#I02)]<A%JHN]=H[C+"UH.Y-&58[*`B9G"5
M!'/'V09@)@8D6]+,0!`<S`00#IQJ6K>NU+X2W:;C2U+Z2`4MK!5,Y2!/5&U<
M=M;DM0#EPH*AFG,_76A02)=)E+YXR&;KVC:=D8^(G:EBXJ3E.J%DS=N0366!
M9;T=$XY%,5(BR_B$,<2E,?@`YXZ-=?;7;*A-)<JAMAY?="B)G^N-.CM=TN#"
MJJ@84\R@R40#I'HXS_1&;X[4:,=`\Q^$?PX4*&J;V=Q4;M5VN7FOB\42&0HR
MD'9:7:'4(4TC6LX)(2CH\A3#FH*\^_0,<I0$P(D.;+ACN;8LCFYMP4ME:!.M
MT%4N"1B<?1#6WKN%.UMKU=\<*0MIL^'/BLB0]/3+JB,']GOL!(71W(W2W1U>
MFO))6HB'L9$RSTAE32-TKH>DKS$B594!$[]C3@.U3B`ZBGD2".0CQ(?GE=F;
M38J+:],J161J`ST-@`8]!.?3`P^7VPNW7<E=O1])4I()23BDN.DDR'5C+HE*
M$'[=[;46QV\YY<J&9"A1^Y"&-7Z)TTQ(@A7,4=&'KM@F)2@0%G3CT61-W1%\
M8>X(X<O([<0NFTU6Q*A^(T:BD3Q]0X@R/I([(;_/K;AL&[_QA*3]RK@%GHU]
MTCJ[LY=?7!D/L]NYI6Y6VNK]N\\_(>I-OU0IJTRDJ<3KKVSK99U)1H)D,8#&
M1@JC3?-1R#2FFH@7+$/\[]OFT;D3>M!\&M$U$9:TR'9,'YC$V<@]R*O&V%VD
MK'CTA]4'/2J?S`CYX-'N#@KU53:6K::V_P!5TE0ET9YB:)@JWK)A*2D52B;T
MID'T\SC8D.O>3K!`PF8E4$K<CC2=34!=!HEM%3;J6Y(J;LVIVWMKFIM)D5@8
MR)Z.F)DO;%TJ;4Y2VEQ#5R<1(.*$PF>!('3T=$:\C>YMIK3:-N*K2RMQ*Y8W
M+K!@R@JNG*TCDI1-&;?UHQ-/K.'!YHYGZLD*CH3.%5.*AQ$>(B.#NV/N"DW'
MMUB]6Y@T](A12EM6.4P)=6&45Y<P-NU>V]R55JKWQ4URD:BXG`8D3PZ<<X*-
M8OL$+[7ULS:V\L%N+MQ`PUT:%IJNHN%D8.LU7\4RJ.+;R;:/=J,E"-#KM$W`
M$.*8`01*.GAB+[QSIVY:;O4VJKM0=?:=F2`D3D<3Z#E$MV7D;N6\VBGN=+=E
MM4[M.))U*PGAT?1!\+/[&;_[?^SR/MAH7<D^HN[=-H7(G(NY]O(-@JWD'TU)
M2500\0L6L8^0DXUH)EBMUG#0[=T3,3IJ!I#$(5^Z+-N#>WX^:)(M2UH!9.`E
M,`X<>F7&)[MNS[SMS81L+=:XNYMH4KQ@3.<NDXC+"(7UB;]3M"[M+2[AKQ35
M5W`EK9W'BJPJ9[4,U(5'4LPO2YUUS10RDLX>N5"NWR0(E'K-"(&U%#AE@Q+M
MMVGN6S7[':6F:;[XVDS0@)`3+JX`?+`7VG<M7;-T-[ANCKU2NA?6`'%E0*@?
MU_)#VD]J?:3=K-4-6[KC4BE-PLW(/V],25951'TG236.9.5B-Z.M5'3*_6F@
MX4J8-S.DDB-G#@ISJKG5$XX9"-U\N>6=*UMYEQ/WE*/XBPB:]?$E0&$SPA[5
M6U^9?-M3FY%ME-.I9\-*E:4:!P"29&"[]C7MPW&6]L)O6L4_G*BVR7RCKPTX
MV/..*4IZJ9&+5=VS9J1DDT93:;R`E(9Z90BB+QN*A3HD$$S@;B$4\V=R62[;
MBM5\:2FJMBV?60#+VI$$C(^GT&)=Y/;=W%;=L7>QU"C2W9#P"52R,C*0)Z<,
M.$1C=P4]>J6OS5\+N!N!5-R+E41<B2HVH)>K)Y_/"25IRJ#Q$D$4F^65;QT<
MJY:"*:3<B:0)B`998(:VT=F9V@I^U4K#+-11:A)`U`%$QCTR.)XF!JOESOKN
M\$45VJG7W6*W2=2B1,+DJ0Z)Y#@(V!N].M'="[3+CR<<L+9])TS%4LU6*;09
M,U6/&$(Z.0V8"!DX]ZL;AQX8JJYX7JIL?+.[5E,N50IK0%''OJ(/S91:UR<M
M#%XWS9Z%Y,Z8$+(&&*$ZQ\XQ@"^S*C&5=;F[004@D5>/;5(:?>-A*!BJITRQ
M>S;9,Y1#1U(/(]$!#F)1Z,5U<BK:U=^9M!2U(UMA9<(^T#.9@Y><5P7:>7==
M4TYTO*0EL'H"Y)PZ)3B4V\=M(QF\?OG2+-FR;.'KQXZ5(DW:M6R)UW+IPJH(
M$20012,<YAX%*`B.+;DI)<33MI)<<(`">G*0_5TQ6XZXVRT5N+TLMHU*4?JX
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MDHU^@FNU=H+D%)4JI#E,`F$@\#<#%$`$!`0##1N%KHKI0N6^K1JIW`9@8'T@
M\#UP[6JEZEJ4UK*REYHS!X8=1PEU9&(E-[J4);B[]S*$CG+H8ZE*TG(>,UNE
MU#DC47IS1Q#*"H)C*(LE4RB(CGJ+BHW>#=7MWF%<;51/OHI6J\!`*U$@).H8
M\<1\D68;-=I+[R_H+E5,L*J7K>I2SH2,2G3P&&<2SJ1XTA2^8B.NG(74(B(B
M/^C&O=Y\<6RV-(_!:9)F0:9O/&<T`XQ6M<0$W5\)P'WASYE&4"K[5^@X(E"V
M^N2S:I,ZG;54-+/7[?-!Q)Q$A&/'R*#PZ8D!T+!XR`R0J:A(4Y@#(##@7O-I
M;6D;>H;XPMYJX"I\/4A92-($Q,#B.F"`\M-2%;C?L]0VT]1.4Q<(<0%$*!`P
M)RG/'T1C79%J*'0OH)U53Z'=!Y`=0YP#4WJ+/@81RS#')\H-PKZNFO#=:^Z^
ME#B-/B**B)DSQ,=CS-L4M+7VL4C+306TX2$)"1,:991U=I]&78IIG2E1-KHU
M0ZM[54K(03VADE$8:+BY!)J1^Q.)X9%DM,,W+4BI3D>G7$%$\RCI$0QX\TM-
MNNRTM'=J.YNBSU#Y;4RV2A(PF,CC&3RZJV_=:NJM[UN9<OC#(6'5#49$XC'+
MLP,#_M%>RX-(6LJBQ]ID)@*SN]6L<FJZ@4U!FOH-"),R+"P)F^E=*1G':HD4
M6*8IDFQ3#J+J$P#[L_F#N"V[1>V9M9+BMP5]7ZRD`E7AJGJQG,&9SB;-V['L
M%SW.UO+<ZD,V*WTY&DD)'B)(E/@0`,!%]K38YN5MW3:%=5'0J2\.W,TD)PD3
M,Q\U*PS?TANHN[EF+%45S)(E$1642!8"#F)QT@)@W:SD-S.L(9W'74[M13AY
MI9/B3=2%+$RO&?RCHC$SSMY;WUUVPM5(9+C3B4_PRE!THDD))`&)';!J-W6Y
MLFVVST,Z@TVCVX-:-$(FBV#O-1LR!)@BI*5&\1*8#+-(A%8G5I\`4<*)E'Q=
M6#/YL<T&>5FQ6:BG03?JIAMIA!];UO#`*R.(1QZ3`B\M-@G?>\7&7E%-GIW5
M./*G*:-9DD'@5\#P$"RVT[/:XWA.)V[MU*XJ!C33J4=,@G'*:4M4]72*:@'D
M0BU'YCM(V&9"8$A/U9T@4_1I)@!#8%OEURBO?.YQ6[MU5CJ+<ZX4B<YKE(E2
M#/!.HD2X$01_,+FK:N4Q3MG:5!3.5;:`H^JD^&#,!*AQ5(`SPF#'FW;;+)/:
MFC35T;<U=/2M.*2S:-/+.`2C:IHZ=,`KQ2Z<A$E;%6:2)D#%(8I$S)JETFU`
M8,>^:W)BJY.L4VZ]LU;OW!%0&U%)*5!:NX5$9@2,?.6W-NFYH?>=N;EI&4U;
MK!4D2&E8&"@`<B)X@3_1#W]K,RSWCT<G4E:S*S.X5`O(JG:W3:-DSA4+9NW7
M^@:F::UDPC5YJ+540<_HER%72,HB5)32<)EY5.4?.>S)K[L^I5ZH5)0Z?K*0
M000/9F!(]/IB'^8%!6<J;\NW6QJ=DK6RMM*C/3,8B>$Y$X<98'`05S2'WM/,
M>7AP7,X'R.D>8_"/X<?(413/M'NY4H*V:VI03TIRI@M>BY#9J?6K^B![3]OH
MIT5+QR*";Z2?:#"'`J1^C!'<@;"A3U;?WDGQ4I#;1E@9GUB.L8#"!9\QNX7`
MBDVNP4EEP^([G,&<@#C*4L<1QS@@7935'M1VJ[*K549-[B+!PUP:O;+7/N:T
M=78H)N_;U=6147A(>024F@61<4S!)LXXR9N)#MC!D&(]YC+ONXMV5%7]SJ"P
MU_!1)"R-*/5U9'UE9F6&,/\`Y7/;6VQL^GHE5].*EQ1=7ZR09J)(2<<@)=<(
MYVU\GMEW/;/WTE0]_;&U+=&R<^VN+1L1$70H>2FIJ,,F,36<!%M&LX9VY<O(
M-QZ2FDF!C*K,B%*`CCK\H7K[8]WAMRE?11U+0;5-"@!B2%DR&.$IG#&.)SK3
MMW<NS_&8K67*FF>*TR4DDX8HZQD>F(^'9-;G"[7-[EK:BEGH,Z&N2X&T%?&6
M<&0:MX:MGK)M$S"X%`<P@JH29+B(AD">L,P$<\$)S7L!W#L]ZG81KJ*63J%>
MUZH,P?2)P._)S=7^7=YLJ=);HZ@EMP'NXX`@=(ZXV$!3:L^)1$#:1T\@']WN
M8!32AU)&2A.?48L)(4%!6!092/2(@8]NT4"]H_=8`_[#VI'CWZ+:#@TN2BE*
MV72ZC-*75B7#-1GZ8`KGJH4N^*IML";K:9GB.[E$P3L[>.Q#:#_R\6K_`-TX
M[`K;W65;SN#N154*$N&!)@R-B-I_R7;D'$"E3#NI8O\`HF4\8?5C\/"T6XXX
M#*R'D'#O#Z8<U2/^!=:),BVK'CD8UC%#T,O="^5*6R;&.FK<2[\31(+)!J51
M)4]9HPRZZ10R$RJ*+TQRAW1+BPE^X/6S:[U0Q(NLT`6DGI#<Y>C"*SZ6G_$]
MV-6YQ/\`PKUQ*52Z"Y(GHRZ8V9-!T-3=LZ+I:WE&QS>&I2BJ?B*8IV*9ID10
M81,,Q2CV2)"$``$W4H`)CCXQSB(CQ$1&OFLJG[A5.5E8=;SJRHD])QPZNCH&
M$64T%MIJ&B:M]$"U3LHT#3T#IZ^/IC)V[!HB[<O4FZ"3MX5`KQTFBF1P[*U`
MY6I7*Q2@HL5N54X$`PB!`,(!EF.-=)*6TM3)0D2$^$;:6D)*E)`"UD$GB9=,
M:W'>\83;ZMSXCEPW,W!#/+B.FNW!``3<\@`O+E@]-ODGEQ2+.*OPQ(^1H"*Z
M]ULI/,JK5E_U9S_?&)RG:,,'+W:!/JH9B2,E:`D70<<O12RS-F8PY=P%GJ>>
M?#%2'F9I'G>5%P33`E:7VSV:L9Q;GY?'J>GYAVURH,D^"J7[7AX"`];#)II`
M[K[2N'BA4TI*2F(,IU/%*5Q,4Y+-F6@V>1C*.]!`[YPP$OE\?I[9S4H*AY0\
M-XJ2)_6R^F"TYY451<>6-6JG$U(4E:Y<$@@S'9$DNZ%'#<6VMQ;?D?#&FK>A
MJLHTLD4HG,P4J6GY"&*\T`("?T4ST%-("&>G+%L%OJ_N5TIZS3J\%U+A'`A*
M@9=LHK@N=&:RW/T4Y!ZF4A).<R%#],:VB\>UR_6WFXTG:.Y5L*SBZJB)$\0S
M%O3LQ(1M4I(&,W8RU(R+1FNTJ"+ETTRJ(J-CGX&R,4I@$`/ZQ[NV[?+>BYTU
M4RTZMG2I,Q-(`QE/$&*WMQ[.W';+JY;ZNC?6EM\J2I(.E1)]75+,&)AW8/[5
M+J;;MLU;U)=R!DZ-G[WUNQK&'HF;15:3<'2T3!H0\0^FHY?2M%R4\?K5_1E2
M$72;@CUA0,.D!1YR[IHMR[H2F@6'*:E:#86/:(SF1@3Z,(,'D3M"X;6VPXNY
MIT5-6YXFC'U1PP/I@X:GDC]S$0J5H&L9B)N6-2"@Y$$1%!W=?6;OI_[BS/\`
M";XJ2YN+GS9N:)`#[Z%?*#%D_*MH-\KK:H$DJH5C'JQB4Y2'LC2O_AN&_P!F
M-L6JV3\GIO\`EFO]V(KGN?YJ_P#\R[_I*@;_`&KHYV&HWO7-C?\`8<U^3`V^
M;;#8%.YQ17B7:!G\L3OY:A+?:V^!H%_2(2/LB?F]]_\`+*"_S>HL,WR=>ZO?
M^M;^DPY/-#^86G_4N_\`IA3>UCX6:MT8`_K**&7<R&FY;\F'3YN0EO9-O"!@
MFM('R1R/+$7%;NK%(44J^Y3)'&1$-R[**W,7.7`N3<IZ@1PYHF(C:?@#'R4!
MG(5,9T>2>HYAXCGZ+C"H@8.)2+'`!XCB,O*#MZDJ;S7WJJ1K=IAX:"0"/7Q)
MQ'>'"'WYI-PU35IH+'3J`:J5%YR4YDHD-.?=.9ZX.P9ND=(Z:B9%2*%T*D4*
M4R9R&+I.0Q,M)B'(.0AQ`0YX/Q333CBFUC4VX`2#,C#JR@-0!-M0`!&4N$QP
MB.=VFE7/)S<RM3O691U!T;341&($`ID4%)1L:H9%4J1<B(F4.[2*(AD.210Y
M8K7\TU^JZOF0FW"98HZ9`">"0X@*44CZV,'3Y=K/3T6RE7$I0I^K?4"5<="B
ME(5*6&$_3"Q6:[3"DK06NHBV;:R4](%HZ`9Q"T@WK",;)R+Q,O7/I`&YH14Z
M`OGBQU=)C&$-7,<2!L3S*6G:VSJ"Q4=CKG&V6`-22$`F9F0"V9S.,^N&=NOD
M-7W[<M==7[U1AQY\JTD%12"!))(<'=&`PR$6#</VB],WYM#5UL`LW.0;BHD&
M!F4R[JQ@^1C7T=)-7[9V+1"&;K+`F9#(2E.41`V6.=S'\P=OWWM&IVLNS7!I
MVH`TJ5)821[6#8D1ECTQM[%Y'U^T=TTVX&KI1.LLDE8EHF"):<5G/,^B/#V4
MU2.HZ^U94T*ARL*CMPY<*HF$0(9Y3TQ'K-52D-P%0K>07#/GD.6.?Y2;A746
M]JVUN-N-,OT,R%)4$ZFU3U3.&HC/JCH>9EBEN%@H[DRI"G:>HT$A0,TJ$I"6
M.!B0;BP^`JBSRTDRAX]_+2CE%A&135U)23UPH";=I',$5'3QVX4$,DT6[=(Q
MS"/``+F/#'QI+KSB64)F\I82D=,S(1\=6TPPNH<5)I""HGHD)F(!S2F*M[7+
MM,JN:QU0N*;C+N5?4THUJ<T;]-%H:S]"1B[*GG!8M1['IN5$8./9)$1ZY$JC
MMYQ,`F'!LM55-RJY=T]4ZE+]=3R.CW?B%S&1(U9$]!G*`,6S4<W>9C[#9534
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M=))"0)W!3>%$.`X![>]C5MS<]7;@D^$72I)RFE1P,H/KEWN-&Z-G4=P007$M
M!*L?:2,OHQB)'V[8"/:075#B`C0UJ.X)LO\`H4T$<P*`CR^_@J.2;2?\CTZM
M0!^\.#'#(GCVP'W/L!>_'Q)7B!E!D!/.7T2^>)@'9W'+_P`"6T0""50I-O=K
MDQ.0P'+K3I:/(H4!+F`B0Q<A[^!3WRTI&\K@C`Z:A1GP,S!C;`J$.;(MKV.-
M.D2S.$.\EQ'Z(E1$/]6/\N^/HBW+AW,-RF/B5"`C%&L8]O#IASUJM%$X5X++
M:\/W3&MXV@_7NVW_`/-/;L/_`))9_EP?.X3X>QZM[/\`Z>$R_NY3BN[:BDC?
M=*PH3U7$F?\`>CA&R:-Q$?A'\(X`*+'$>K'T3G]S\884*-;)O<X[ZMT`?_IJ
MX7^_[L,'IMW'EY2M?_&),_[H&*YMUO2YE5:9?]V7_OC&P[NQ;UM=>S586Y=*
M%1)5M%K13=<V6EM(G9)K1;HW0#:2224$>X!<5P[]L7^:=K7&Q$Z?'84`J6J1
M!U#"8XCIBR[:-W.W[E;[TG$L.-JEE,2`4)]8GPB*&<E5VQKH".$7$!6E`U,@
M8Z"Y3E6C:AI]^FJ0#@`$$Z17C<#</%.D/#,H\:@U)NVR]V`5)4U6TE25I!P(
M2E4P?WACU=<6>M/VO=VU0VP0NWUU*4DC$3TR(ZY=D2F-N-_*9W#6SAZW@5FR
M,F1)NSJZ!!8BKRG:B21+Z8S72+I-Z.L<!4;*Y:%D!`0',#`%K_+G?UNWYM:E
MN]J<2NKT!#R`05)6`)CAAC.<N,5L[YVA<=F7UVU75L_=TDJ:69C6W,Z5`8C,
M$$3P,+PJW1<'3.JDDJ*?C)'43(<Z1QR\=,YBF,0X@&68"'#$C-.A*U!*E!TY
MB>79U_/#*6E+I!4A"V5&>(Z.O']$<JKD0*<ZABD(DF<ZBBA@3(FFF43&.H<P
M@0A"@`B(B(``!F.$M2&4%QTA+(!*E$B0`XF<I"-AQ)$BTA2G522E($YG@,,H
M2VVUYZ'NZ^KAK0<D2<84'4"5,2<XU.12)?3'H*3YVE$N"CD];,!5!(ZQ<TSJ
M`.@3`&>&IMW>%CW<Y4M65Q3C5,YH6N4DE7V3Q'7':O6W[K8&V?Q1I352^UXB
M4*P.G*9GCUY>F(S.[<,]SM\P/FG_`$BS6>H,A``,@/(<N8!P^'%7W-Q#:.;5
MQ*U24JO0G+@3+5V='SQ8?RPU_P#U9;2!-(MZS/KD<(E*40Z0>451[MJH59JY
MI6`706*/!5%>(:*)*$X9"!DS`//%IMCJ:8V"DJ-8\-5,WECD@"0`SBN6Z"5V
MJ4R5K34.<,,5',P-#M89N,0M';ZG%')`EY2O?I1DS`Y.M481,)($?.C$$VHB
M**KU(FKD)S@&>>!J\W%;2IV+34*E@5SM4'$H.>E,H(+RST%4_O%VX4R==.U2
M*0HY`$G#'I]4X0G/9%<&U]ARSS=T$/\`@*B##5\G&HHO84)(UMDGKQ,O_&.O
MYG%H=K[2`?7#+LQT=V%,[67A9FW8=%RR<?\`RW+#^/#K\WF.R*`_^^/T".1Y
M8U:-VU_V:(#Y2(Q#LC,OV7OF<"@!CU-1O$`X@4(B8\7/N\0$?NXY'E`"4V&[
M2'KFK1CV&-SS-(4G<-N0533]T7_IR@P>68"'3W<&2$:5A4\A*!C2<$]41N.T
MMI9[!;I9V361,5E6%*4I-QIQ*8I'!&L>:#?@500T&.B[BQ`W'@"A,^>*S_-+
M055MYF&M<]2EJ:=LMKE/4I#8!3+TB4YP>WEXKJ.NY>*I4XU-)4+\1,_9<65!
M75(&"L["JRHZY^W*C$/HV#>U)0C;]C*I1<Q\>H^2=1>98UVXUH&5,23BS(J$
M.(9&,!RYZBFP6?(6\[6W?R_HDM,4JKC2M>&\DMH*DJ&.,TDF8(,X&CG#;+GM
MC?=:A#M2FAJ5>,T=2I*2K`RD1DH$>@"'G&IJF1'QJ>@`[A!&'CA$1'+/AZ,&
M)F-GL*T>I2TBFYX_PT3GZ`D?/$7HNMV5-(?J9\9K4`.W4?HCR@%*P<G%LTV\
M)%RTT=VWBTF[1BT?/2LD#NWX-P02*LHBU;)ZEN.D@"7,<Q#'QABSVRL33MM4
MS-2M*M(#:4*(`FKUA,F0QRC$:JXU=.M]3K[U*@@*FHK2DDR$Q(`3.$XS/':C
M5@#';?;]Z?L;8*H-N5O*D1<WQO2Q6IV89PJQ'CZ@[;/""2IY6;]&5,I$O:E8
M'&.8)GTK*%756*`%2`1EOE)LNHO^X6;K5)2+73*F2LR"B,@)YR,C\D0?SIWS
M36&P.66A6I5UJ1I`0)E(XSEE/]<#<^S<1UNFUX]PLQ-R<8VN8A0E)05$0C]1
M%O)NJ8?2\@_K![#(N>K4<*(O(V-3<%2U'32$@F\4V8O_`,P]34J:I&Z0A5#C
MKTJ!TJ&`"@#AA.41YY<:&G;K*UVM24UY/\/4DB8,IE).>/1$P`H@8,P[HCSX
M=W`Q-D%`*<H+((*/55G%&#,!Z<N'P\<>R3I.G.4?"F:TJ5W4F?;$-G[1E35O
MF&Y2RU64Z_C5;@U-:Z3CKB0\>=-=^V94U-(!1DO,I-Q44;N)!M*NVR76Z3*(
MM"B7,I<\%-R!K5+LU;2UB_\`@D.-E`)`]90621/A.4X#SS'6U)O]'54B3X[S
M2_$(&82I(`PXR,)WV'&_:`VQ76J6Q=X)PU.VCO<[CG4)4<IUR,'1=SF12L&3
MB5=*_H(N$JV-.5HNX,!$T7*#<5#`03&+N<YMJB]43=^MOA+K*82<2%#4I'V1
M[1!QZ>B,'(S=RMOUIVY6^*B@?,T$I)2E?VL,`1A&1_:#+"U936YVFMRK6.7D
M+5W?H"F(`*KCB"ZAV%9TDU<L/HF1D&Q3H-3R\$9LY9B8P$=%*J5(3'()<+D5
MN&UKLSECJEH%73/+.A9TZDKE(I/2DS!GTB%YA-LW!.XF]PTB%FDJ6$IUH!.D
MHS"OVLQ+HA.=H';B7UVR6'IO;VWM)1MVC4@0\%:^:E9J=82S"/=N#J1E.R47
M",G*U3`P=.1(T!$Z#I5(2I>-D4V/>[^3%DOMX<O3M5]VIUG6L:TXRQ)&/5*6
M75&CM#G=?MO6=%D:I?O+J!I02A<P3@!+#B8DO;;JUNY:'9M7.X_?95+:$N76
MD?4]VJVB7YDXB*MS3JD/Z/0MKH*&,N9&-=QT,T1(+(AU'2\H^5!0ZJQC#@=K
MW1VFHW8W:MK:E6]MQ"$DYJ5,`F8P(_5AA!,V6MNM-LQR\[L4$U[K*UJ$B-*2
MDR3(C`XRB"KM_N(QMYN1LU=J<;.$8.DKV437LR51!=46L*QK)E+R2ITR$$1]
M"9@<^D,Q'J^',,&O?V45&T:JW-NMEW[D`#/`D-F8Z9P"UAJ54>[:6[/-.AA%
M<5$:3,)\2<^C+&-F%`5+!5="1=3TS*L)VGII@VDHB9BW2+V/DH]VD"[=VT<H
M'.DLBJD8!`0$>?3BOUY)84I#N"DYQ9%353-73IJF22PI&H&1&!ZLX^*CJ6`I
M"!E:HJ>7CX"G8%BXEIF:EG*#*,BXUBF+EV\>NW)TTD$4D4Q$3"/W,\>F6W'W
M4LMIFZI02!TDY1Z>J&F&%5+ADRE!43+@,\,XUH>XVX<?='<K>^[4"U=*P5<7
MGKFN8`AVJZ:CB&DZN>RL2)B'#,BCECU:F0CGJ-QP?=BI%4VU*6V.J1]X30);
M,E"6H-A)'7CA%<.XU.56]ZJ\,MN&D-Q4Y/29Z"Z5`GLC8ZV)N_1%^;0V]NG;
MV983M,5I2L/+-'3%9-8K-PJP;B^BGZ9#F.SDXIYK0<-U,E$E4Q*8`P"%UHW[
M=7OT#J=+S;BDD''"?Z1*+#;/6,7:U4U73F=.MI*@>R7S$$=D,MWL[%D[W+N+
MFVN!C&70;M4DYB(=+>B15;LVR8I-S*KB44V%2()E*1-P;]&NF0$U!`<CX%#G
MCR%:WM_^0;9;;1N!*)+2</&"1(!)&`5^U(&"/Y3<X'=FN_@NX5.+VYCH4G$L
MJ4022,RDF9DF9'S`,D!4E^MJE<K+L_VHM=5K50B#^.EF2B+&903U"1N^8NR'
MB)QAQ$Q3!UI<LQ(8.>`?M]3S(Y.WF5*BKHJII1U-D%2%8R,Y>J01AV06]PM>
MQN:ME0\M=-5TQ3I#H(#B>,A.2DRGZ9P]6)[6&\S)@5"8M[;>;?E2TA)HK3L2
M4ZFD`!8[))X\3'4(9B!#$`1Y`4,3G2>;_=3+*&ZZWT;M5IEJ]<*,L)Z1A$4U
M?E>VMBJDKZQIM1G*2"GY9<(2.K=T6[+=S(EMY3!7IX^65]'<T;;*.<,6B[=0
M0X3\V==9X1H!?/"Z=(M=/,O<%KW3FESGYNUIL-F#K5,YDVT@H!"O5.M?U1.8
MQSAPVKEMRDY7TGXY>%>*^V,5NJ"L1B-"/K$]`G*#%;)]M\QMNM<[@:FE&C^J
M:IF?VDG&T=I-'0RI6;9FVAV:V13/2M$&X=8KD!3*&$"AIR$3.Y(\N'N7&U#;
MJ]Y;]U?6''@<="N*4DYP*?-S?K7,#=";I;VRW0LM^$U.0FC'&0R[8$AVCUF)
M^@;ZS]Q0BW)Z*N:HSEV,T4HJ,$*C28MF,U$.U@+H9.Q4;`ND4XAUJ:F9!$2F
M``[\R^Q;C8-].;G+*W+37D+0I`,D+`R63@F1^6"H\O6];7>=HL[9>=0+E0ZD
MK;)D5-DF11/.0SB[V@[2RYEK[>15`25&4W6Y:=8(1%-3C^3DHM\DS;9HQS"6
M1037)(G9I`1),2"BJ9,@`8!'CC/LKS-;OVQ8F;$]0L5;C?JI6DZE`<!I!F3V
M1H;P\N^VK[>W[S1URZ:D>F5MX#$XJ(*O5`/5"7[@8+<1<RB3;I+XE4@XN7J*
M)I*BZ=?,UXHR<5(LY:0!>&A'"AE8B#;BR#2=<?2'JA]8Z@`!PWN9UKYE[NL:
MN96\DEIAQY#5,P$JU)2M)4#HE@)=LX[_`"\N'+_;M[_^O]FKUU#;*G7GRI(0
M2VH)4DK)$U$GT`=$.`[-12\U%UC43R*M/4]1VYKJ.CFDG4.MK3\9%O(ETNJR
ME6CRH#,F\JEU+M0BJ;?6IH$!)F/`9)\KS&]+)>:H&V5*K'7(3-9TH`*>/KD=
M>`QA@^89>S+I1,O"YTS-WI=8*/6<*M7#^&#(=9D)@0MG:Q5W"GIBUUO6SI!S
M41ZD>U3(QJ:A574=%-(E2/:K.RE$10!^Z>B5,#``J%(8P<`P]/-M=:9^P6^P
ML!3EQ\<NJ2@:]"9>UIGC#2\LMOJ!=KA>7-**'PDMA2R$ZE3X`RZ/G$8;V3%=
M049(W<M_(/4VDY.A3510;5R<B`R:,6E)1\HBRZTQ17=,Q=HG,F7,PIGU`&0#
MCC^4BZ-TXNEBJ4+;K5*0\C4-(6F7LD\9&<=CS-6YQVJMUX8*7&`VMM>@ZM'K
M3&J7`P;HHZB@(<A#,,&^%I<&M!!2>(@2QEQ[<(8MOHVM.-QE!,7U)E;IW+H<
M7;JG/23@@A/1KHA%).EUW`ADBHZ4;)+-CF'21PGD(@50XX@3GYRE<YE[>;=M
M00=Q49*FM6`4.*9]/1PB6^3O,-O8NXU?B"E_@52`EX)QTGV52XRGC+&4`=MK
M=>\VU:X+QQ`FD:.J-`P,:GI.IHY8K"60;+"?T":AW0-SJ=4H!NJ<(G*H03"*
M:F0CF`FU=V;XY-[@J'J-HL5864O-/`ALD2!EP,Y=X8=<Q!K7S;&T>:EE;34J
M;?IM$V'FE)\1(Q(F<Q*9F(?0MVL5U7K)%E%VHHE.H'75M47(RE0R2!W2A1(4
M6L&@"+IPH=00$J0+#T9CB>FO-UNFJITTE-:&/Q!8DE2)K!6<B`DF6/3$&N>6
M6P4M3XE5=W4TP,U)44H]09XG`X=$/AV=4!>RH9::W$[CWST]<5/$)P5!TF]0
M!@A1-&N%TWKU1&$3`$89W4#A!(>J'4X*W2+UQA.<0"?>3]@WK7N.[XYB*<-W
MJ6M+3"^XT@F94D<"I.'HB(>9MUVE1)1LW8B$?@U.YJ=J$CUWG`):5*/>2G/H
MGEE!"\$!$/PUFK_:Z<^JYY\OM?[6>:3]>?RCH^+EC=I/AO[?O'N=W,_/'`JO
MS'_!=WV_><(YI'VJB?JO><-[(>T_D?ZJ^4Z?BY8SU7PZ_B?W^[D,X^4OQZ?@
MLO[/OYG*'/E_?>:\HWP\^[\;IQR^`]$=Y/'TF.1[OD<ORX7`^B/?1Z8;#6WM
M7+_5=\ZW]MO:OS)O6_RGZOXF-VG]PGW^7L]WLCA5OQ!^"_O.]&+K>9/]3?S9
MO+\WR#R_D^GO8VFN_P#XOLSC0<[G_;(O^Y'ZM-8_5K]ETO?[]7SS!?7_`/,_
M\7^YC<LGYVCX[,_#^_S']#V1K[F_(E?EV0^*]SD<OM?5ZIP"_L]OK$1']C5Z
MP_J7][/G2^[?^6?BT8EO>'Y`O^9^X/B/<YCO_9Z.N40SL?\`F=G^4_>'X;W^
M1[GVHD5W)]G"^[7U@S]YOL]YX>7\X_J?CX@AC,]_O>SZ?I_3!&W/N*]UF/>]
MW+^DH0?]^;ZG/<_NO)+]_P#%C?\`8'Q6?9#?7[P_E>7'.'&T#[*QGL3S6]W_
M`+)_.%/5G>_6?*9XYG]JO/MS[8=3'LY>[]G+L^ST1V5][+2?L3Y)/;_V5\\7
MUG\7\WXV6,+/#]L99]G7T=<?5]X_L'/]/5T]4X;@;D/U.NYSY\OX71CN-=X?
M&=\Y>GAU]/7#>/N7/@.X/1D.]U?5[(7&UGJ%7W7?/W'NL]1>;3^<?SE^L[V6
M.;4>_7W^][7>_>ZXZMN^&;]UW1[ON=D*47SAO->4'/GY).??Z,>/9XQTU=SC
M"&WX]F?ZC?-']]_J+R3_`#?X_P"[B-M]?ECGY+W?\=Z>'5^F<.7:GQR?S7O?
MX//^OIZH$<^]H@_LQN;GE\P\\7SORW3WL""Y^=M__P`^[Q_:SX03E)^2J_GG
MNC]G(YP6/;G[(D]PGFT/<+ZA\@GSKX_1WLL%_L7X(?DGNQ\#Z?:ZNCK@:]X?
M&G\U[Y^-[V7#K_1#@#<C>:\D?PA][I[^)$5WD?M#Z#$?K[CG=[OZLX2:^'NU
MG_=1YDOOE]@?-G];?&_,Q'V]_P"7:G\K[Y^.^'S'?Z^CKE#MVG^<L?&Y#X3W
M^1[O5T]4X&C8?WEI?V=?SS_JE[2<D?9SY;\WOY8&3EG_`#2K^0???X3W^9[O
MV^B)ZWQ^0)_F_P!W_;^ZX=[[/3#^]R7LM0WN7]Y5.^^GV3]6SOJS_O)_$OBZ
M\$9S%_+Z/X#XEKXCN=P]S[7U>J(+VO\`$U/Q7P[GN>_WT][[/UNN%]C/5L5Z
MJ^9-_5GJ[S)?5G\B_,^)EA\4GY.S[K(=SN?N]4-Y_P"*7WOWN]^]"<5'Z\?>
MZ+R4_:/UYY(_/>]^9\7'-NWQ:_@O<GWO>RX_9C)2^X/O._[/=SX]?1'EA?6[
M'W->=-ZE]=>;#YC\OT_%QIV+W[/Y?W![KO9<.J,]R^#7\1G_`&G<_KA9B>2'
MF^6'L<XY3/NAEEPRCY-S_O?,.?+N<N_C&]W.';&0YB&+[P/,,/JD?-T_K!>M
M^2WJGY#\SOZL#]S@]TC^5?=?]R]YF<OL='7JB7^6'Q*OY@[X^`[O[W7"%;4_
M:]C]0SDC[L?;OS_^(_*_F_&RPPN5GYE_^E=X?`]_^OH[8<G,[W*/YF[I^-[N
I8RZNGL@K9/+'S?DASY\\%\C/VLAGW>S^F4#TWW>W^G]/3'JQDCW'_]D_
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
